Dai Guang-hai

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Ann‐Lii Cheng, Gerardo Cornelio, Lin Shen et al. · Clinical Colorectal Cancer · 2016 · 25 citations · Full text

Medicine, Oncology, Pharmacology +15

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer

Shiyun Chen, Miaomiao Gou, Huan Yan et al. · Disease Markers · 2021 · 21 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.

Zheng Li, Qi Xu, Zengqing Guo et al. · Journal of Clinical Oncology · 2024 · 20 citations

Medicine, Oncology, Pharmacology +15

Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.

Jihui Hao, Zheng Li, Qi Xu et al. · Journal of Clinical Oncology · 2024 · 18 citations

Life Sciences, Oncology, Pharmacology +17